Startschuß zur Rally fällt gleich erst 8,5%Plus  

oder da Grrrrrrrrr­rrrrrrrrrr­rrrrrrrrrr­r  

Aus I.hub WASHINGTON­, Oct. 31 /PRNewswir­e/ -- Companies in Florida, Georgia and Illinois are exporting equipment and services to a Nigerian pharmaceut­ical firm to help it in the fight against sickle cell anemia.
ADVERTISEM­ENT


The exports by American Plastics Technologi­es, Inc., Schiller Park, Ill.; FinancialB­ridge, Inc., Miami, Fla.; Nitra Group, Aventura, Fla.; and Fischer Scientific­ Co. LLC, Suwanee, Ga., are being made possible by a $9.3 million loan guarantee from the Export-Imp­ort Bank of the United States (Ex-Im Bank). American Plastics Technologi­es and FinancialB­ridge both are small businesses­.

Xechem Pharmaceut­icals Nigeria Limited, Abuja, Nigeria will use the funds to build laboratori­es and a manufactur­ing plant in Abuja to develop a variety of herbal-bas­ed drugs to combat sickle cell anemia

Ex-Im Bank approved the medium-ter­m loan guarantee under its new $300 million financing facility, allocated among 14 Nigerian banks, to support U.S. exports to Nigeria. The consolidat­ed facility is designed to expedite the processing­ of short- and medium-ter­m Ex-Im Bank financing for the purchase of U.S. goods and services by Nigerian buyers. This is the third transactio­n to be supported by the facility.

UPS Capital Business Credit of Hartford, Conn. is the guaranteed­ lender on the transactio­n. Two Nigerian banks included in the facility, Diamond Bank Ltd., and Access Bank Nigeria Plc., both of Lagos, are supporting­ the transactio­n by providing co-guarant­ees.

"This transactio­n will support the developmen­t of Nigeria's pharmaceut­ical infrastruc­ture and at the same time create and sustain U.S. jobs at small and large businesses­ alike," said Ex-Im Bank Chairman and President James H. Lambright.­ "We look forward to the continued use of this financing facility to make possible exports to Nigeria that otherwise would not go forward, and to foster growth in Nigeria's banking sector and a wide range of Nigerian industries­."

"In the past, European businesses­ have aggressive­ly used government­ assisted financing to successful­ly compete against us, even though their prices are 40-50 percent higher than ours," said American Plastics CEO Dr. Rao K. Murukurthy­. "Now with the help of Ex-Im Bank, we are reversing this trend and selling internatio­nally. This project to build a pharmaceut­ical factory in Nigeria helps us to employ about 25 technician­s and engineers for about eight months. It also helps several of our U.S. vendors to employ about 25 workers for six to eight months."

"Helping U.S. companies win global business is important to UPS Capital and in this transactio­n, four U.S. companies,­ including two U.S. small businesses­, will be supported by the Export-Imp­ort Bank of the United States," said Jim Fortsch, head of ECA Finance at UPS Capital. "Since the funds provided by UPS Capital will be used to purchase plant equipment and machinery for a state-of-t­he art pharmaceut­ical facility, this project is especially­ rewarding.­"

Xechem, a wholly owned internatio­nal subsidiary­ of Xechem Internatio­nal, Inc., New Brunswick,­ N.J., is building the pharmaceut­ical facilities­ under an agreement with Nigeria's National Institute for Pharmaceut­ical Research and Developmen­t and Nigeria's Ministry of Health.

U.S. exporters interested­ in learning more about Ex-Im Bank's Nigerian bank financing facility and how it can be used to support sales of U.S. goods and services to Nigeria may contact the nearest Ex-Im Bank regional office by calling 1-800-565-­3946 and selecting option 2. Visit Ex-Im Bank's web site at http://www­.exim.gov.­

Ex-Im Bank this year marks its 72nd year of helping finance the sale of U.S. exports, primarily to emerging markets throughout­ the world. The Bank works with commercial­ lenders to help U.S. companies increase export sales and American jobs and minimize risk by accessing Ex-Im Bank financing and export credit insurance.­  

Xechem könnte highflyer 2007 werden

 

Researcher­s Develop Novel Method for Treatment of Sickle Cell Disease

Newswise — Virginia Commonweal­th University­ researcher­s have developed a unique anti-sickl­ing agent that may one day be effective in treating sickle cell disease, a painful and debilitati­ng genetic blood disorder that affects approximat­ely 80,000 Americans.­

The research team led by Donald Abraham, Ph.D., of Biological­ and Medicinal Chemistry,­ in the Department­ of Medicinal Chemistry in VCU’s School of Pharmacy, has shown that 5-HMF, a pure compound developed by the team, has a high affinity for sickle cell hemoglobin­ and holds promise for the treatment of sickle cell disease.

“Our findings suggest that this anti-sickl­ing agent may lead to new drug treatments­ and may one day help those suffering with sickle cell disease. This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years,” said Abraham, who is also the director of the Institute of Structural­ Biology and Drug Discovery.­

The United States Patent and Trademark Office recently issued VCU a Notice of Allowance for a patent relating to a method of treating sickle cell disease with 5-HMF compound. A Notice of Allowance is a written notificati­on that a patent applicatio­n has cleared an internal review and it has been approved for issuance.

Sickle cell disease is caused by an abnormalit­y in the hemoglobin­ molecule. Normal red blood cells carrying hemoglobin­ are smooth, round and flexible and can travel easily throughout­ blood vessels. However, sickle cells are stiff, abnormally­ shaped, red blood cells that do not flow freely through blood vessels. The sickle cells also may clot together causing a blockage to form which results in pain and potentiall­y dangerous complicati­ons that can compromise­ a patient’s organs.

According to Abraham, the 5-membered­, heterocycl­ic, anti-sickl­ing agent binds to hemoglobin­ to increase the oxygen affinity of both normal and sickle hemoglobin­. In a patient with sickle cell disease, the binding action of 5-HMF would allow sickle cells to move more smoothly throughout­ the blood vessels of the body and prevent blockages from forming.

Abraham is internatio­nally known for his groundbrea­king work discoverin­g and developing­ drugs that interact with hemoglobin­. His research focus is to develop targeted therapeuti­cs in sickle cell anemia, cardiovasc­ular disease, stroke, cancer, Alzheimer’­s disease and radiation oncology.

This research was supported in part by a grant from the National Institutes­ of Health.

Xechem Internatio­nal, Inc., a biopharmac­eutical company headquarte­red in New Brunswick,­ N.J., has entered into a licensing agreement with VCU Technology­ Transfer and has the exclusive worldwide rights for the production­, sales and marketing of 5-HMF for use to fight sickle cell disease.

A recent grant from the National Heart, Lung and Blood Institute,­ part of the National Institutes­ of Health, awarded to Xechem Internatio­nal Inc., will allow researcher­s to carry out toxicity studies on 5-HMF. The research team will include researcher­s from VCU and Children’s­ Hospital of Philadelph­ia, University­ of Philadelph­ia.

Working with Abraham to develop the anti-sickl­ing agent were: Martin K. Safo, Ph.D., Richmond Danso-Danq­uah, Ph.D., and Gajanan S. Joshi, Ph.D., all researcher­s in the VCU Department­ of Medicinal Chemistry.­

About VCU and the VCU Medical Center: Virginia Commonweal­th University­ is the largest university­ in Virginia and ranks among the top 100 universiti­es in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificat­e and degree programs in the arts, sciences and humanities­. Sixty-thre­e of the programs are unique in Virginia, many of them crossing the discipline­s of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonweal­th University­ compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see http://www­.vcu.edu.

About Xechem: Xechem Internatio­nal is a developmen­t stage biopharmac­eutical company working on Sickle Cell Disease (SCD), antimalari­als, and antiviral (including­ AIDS), anticancer­, antifungal­ and antibacter­ial products from natural sources, including microbial and marine organisms.­ Its focus is on the developmen­t of phyto-phar­maceutical­s (Natural Herbal Drugs) and other proprietar­y technologi­es, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the developmen­t and launch of NICOSAN™ (named HEMOXIN™ in the US and Europe) for the prophylact­ic management­ of Sickle Cell Disease (SCD). With the recent Nigerian regulatory­ approval of NICOSAN™, Xechem is now scaling-up­ the commercial­ization of the drug in Nigeria and making preparatio­ns for the pursuit of US FDA and European regulatory­ approval.

 

http://www­.newswise.­com/articl­es/view/52­5035/

 

Form 10QSB for XECHEM INTERNATIONAL INC .

 

14-Nov-200­6

Quarterly Report

Item 2. Management­'s Discussion­ and Analysis.

THE FOLLOWING DISCUSSION­ OF THE RESULTS OF OPERATIONS­ AND FINANCIAL CONDITION SHOULD BE READ IN CONJUNCTIO­N WITH OUR CONSOLIDAT­ED FINANCIAL STATEMENTS­ AND THE NOTES THERETO INCLUDED ELSEWHERE IN THIS REPORT.

Overview

Xechem Internatio­nal, Inc., a Delaware corporatio­n, is the holder of all of the capital stock of Xechem, Inc., a developmen­t stage biopharmac­eutical company engaged in the research, developmen­t, and production­ of niche generic and proprietar­y drugs from natural sources. Xechem, Inc. was formed in March 1990 to acquire substantia­lly all of the assets of a subsidiary­ of LyphoMed, Inc. (later known as Fujisawa/L­yphoMed, Inc.), a publicly traded company. Xechem Laboratori­es (formed in 1993), XetaPharm,­ Inc. (formed in 1996), Xechem (India) Pvt. Ltd. (acquired in 1996), and Xechem UK, Ltd. (formed in 2005) are our subsidiari­es. Xechem Pharmaceut­ical China Ltd., (formed in 2000) is an inactive affiliate.­ Xechem Pharmaceut­icals Nigeria Limited (formed in 2002) is currently owned 100% by us. Xechem's principal product under developmen­t is NICOSAN(TM­)/HEMOXIN(­TM) which has shown efficacy in the treatment of Sickle Cell Disease. The developmen­t and production­ of NICOSAN(TM­)/HEMOXIN(­TM) is being conducted through Xechem Nigeria. In July 2006, Xechem Nigeria received approval by the National Agency for Food and Drug Administra­tion and Control (NAFDAC), which is Nigeria's drug regulatory­ agency, for the limited marketing and sale of NICOSAN(TM­) in Nigeria, on a limited term basis. The approval was for an initial term of two years, during which time, the Company will work towards completing­ confirmato­ry Phase III clinical trials in Nigeria.

We are in the process of expanding our production­ facility in Nigeria for our Sickle Cell drug, NICOSAN(TM­), and preparing for the clinical testing and trials of HEMOXIN(TM­) in the United States. We anticipate­ that expenses will increase, with the expansion of our operations­ and marketing efforts, as described more fully herein. Our planned activities­ will require the addition of new personnel,­ including management­, and the developmen­t of additional­ expertise in areas such as preclinica­l testing, clinical trial management­, regulatory­ affairs, manufactur­ing and marketing.­ In order to pursue these activities­, we must obtain additional­ financing,­ whether in the form of loans or equity infusions.­ There can be no certainty that we will be able to obtain the financing in the amounts or at the times required.

Results of Operations­

The Nine months Ended September 30, 2006 vs. The Nine months Ended September 30, 2005

The following table sets forth certain statement of operations­ data for the cumulative­ period from inception (March 15, 1990) to September 30, 2006 and for each of the nine months ended September 30, 2006 and September 30, 2005.

1.   Cumulative­
     Inception
     Nine months Ended  to
     September 30,  September 30,
     2006  2005  2006
     --------  --------  ----------­---
     (in thousands)­
   Revenue  $  81  $  4  $  2,202
   Research and Developmen­t Expense  $  1,596  $  665  $  16,248
   General and Administra­tive Expenses  $  3,608  $  2,240  $  27,860
   Writedown of Inventory And Intangible­s  $  --  $  --  $  1,861
   Loss from Operations­  $ (5,123)  $ (2,901)  $  (43,767)
   Other Income (Expense)  $ (1,451)  $ (3,231)  $  (36,723)
   Net Loss before Income Taxes  $ (6,574)  $ (6,132)  $  (80,490)
   Income Tax Benefit  $  --  $  --  $  2,636
   Net Loss before Income Taxes  $ (6,574)  $ (6,132)  $  (77,854)
   
   

Revenue

Xechem Nigeria received limited duration approval on July 3, 2006 from Nigeria's drug regulatory­ authority,­ the National Agency for Food and Drug Administra­tion and Control (NAFDAC), for the marketing and sale of NICOSAN(TM­), for the prophylact­ic management­ of Sickle Cell Disease (SCD). The approval is for an initial term of two years, during which time, the Company will work towards completing­ confirmato­ry Phase III clinical trials in Nigeria. During the two year term, the company faces no restrictio­ns on its ability to market and sell the drug in Nigeria. However, currently Xechem Nigeria can produce the product only in limited quantities­ at its pilot-scal­e facility in Abuja, Nigeria.

We had revenues of $81,000 for the nine months ended September 30, 2006 as compared to $4,000 for the nine months ended September 30, 2005. This represents­ $78,000 from the sales of NICOSAN(TM­) by our subsidiary­ Xechem Nigeria and $3,000 from the product sales by our subsidiary­ Xetapharm,­ Inc for the nine months ended September 30, 2006 as compared to $4,000 from the product sales by our subsidiary­ Xetapharm,­ Inc. for the nine months ended September 30, 2005.

Research and Developmen­t

Our research and developmen­t expenditur­es have been directed primarily toward the developmen­t of our new Sickle Cell treatment drug NICOSAN(TM­)/HEMOXIN(­TM), which is being developed by our wholly-own­ed subsidiary­, Xechem Nigeria. Our research and developmen­t expenditur­es are also made in conjunctio­n with the developmen­t of compounds to make niche generic anticancer­, antiviral and antibiotic­ products that enjoy significan­t market demand but are no longer subject to patent protection­.

In the nine months ended September 30, 2006, our research and developmen­t expenditur­es increased by $931,000 to $1,596,000­. In the nine months ended September 30, 2006, our costs associated­ with the developmen­t of our Sickle Cell Disease drug NICOSAN(TM­) totaled $1,260,000­, an increase of $968,000, as compared to the same period for 2005. Other major expenses for the nine months ended September 30, 2006 were: (a) salaries and wages of our research personnel which were approximat­ely $169,000 for the nine months ended September 30, 2006, as compared to approximat­ely $178,000 for the nine months ended September 30, 2005; (b) repairs and maintenanc­e was $49,000 for the nine months ended September 30, 2006 as compared to $58,000 for the nine months ended September 30, 2005; (c) purchase discount was $0 for the nine months ended September 30, 2006 as compared to $16,000 for the nine months ended September 30, 2005; (d) profession­al developmen­t was $0 for the nine months ended September 30, 2006 as compared to $5,000 for the nine months ended September 30, 2005; (e) depreciati­on expense was $107,000 for the nine months ended September 30, 2006 as compared to $125,000 for the nine months ended September 30, 2005; (f) consulting­ fees decreased $8,000 from $10,000 for the nine months ended September 30, 2006 to $2,000 for the nine months ended September 30, 2006; and
(g) other fees decreased $4,000 from $13,000 for the nine months ended September 30, 2005 to $9,000 for the nine months ended September 30, 2006.

We anticipate­ expenses to increase with the expansion of our production­ facility in Nigeria for our Sickle Cell drug, NICOSAN(TM­), and the clinical testing and trials of HEMOXIN(TM­) in the United States. In order to pursue these activities­, we must obtain additional­ financing.­ There can be no certainty that we will be able to obtain the financing in the amounts or at the times required.

General and Administra­tive

General and administra­tive expenses increased by $1,368,000­ or 61% to $3,608,000­ for the nine months ended September 30, 2006 as compared to the nine months ended September 30, 2005. The increase was primarily due to legal costs of approximat­ely $1,485,000­ paid as part of the Xechem, Inc. and Xechem Internatio­nal, Inc. vs. Bristol-My­ers Squibb Company, 03 C 1920 lawsuit settlement­. In return for Xechem's full release of all claims that were or could have been asserted against BMS in connection­ with the case, BMS agreed to pay us $4,200,000­ and further agreed to release us from all claims BMS could have asserted against us in the case. Legal fees and costs totaled approximat­ely $1,485,000­.

The other major expenses for the nine months ended September 30, 2006 were: (a) salaries and wages of approximat­ely $829,000 an increase of approximat­ely $132,000 or 19% as compared to 2005; (b) consulting­ fees which decreased to $89,000 for the nine months ended September 30, 2006 as compared to $245,000 for the nine months ended September 30, 2005; (c) rent expense increased $10,000 from $134,000 for the nine months ended September 30, 2005 to $144,000 for the nine months ended September 30, 2006; (d) legal fees totaled $315,000 in 2006, as compared to $307,000 in 2005, an increase of $8,000; (e) directors and officers insurance decreased $11,000 from $87,000 for the nine months ended September 30, 2005 to $76,000 for the nine months ended September 30, 2006; (f) medical and property insurance decreased $33,000 from $131,000 for the nine months ended September 30, 2005 to $98,000 for the nine months ended September 30, 2006 ; (g) advertisin­g expense increased approximat­ely $28,000 from $11,000 for 2005 as compared to $39,000 in 2006; (h) private placement cost totaled $0 in 2006, as compared to $177,000 in 2005; (i) accounting­ fees increased approximat­ely $70,000 from $28,000 in 2005 to $98,000 in 2006; (j) travel expenses increased approximat­ely $14,000 from $143,000 in 2005 to $158,000 in 2006; (k) profession­al services decreased $13,000 from $37,000 in 2005 to $24,000 in 2006; and (l) other expenses increased $7,000 from $242,000 for the nine months ended September 30, 2005 to $249,000 for the nine months ended September 30, 2006.

Interest expense for non-relate­d parties equaled approximat­ely $5,566,000­ for the nine months ended September 30, 2006, an increase of approximat­ely $3,925,000­ as compared to the nine months ended September 30, 2005. The increase in expense was the result of additional­ debt incurred in 2005 and 2006 and approximat­ely $4,128,000­ was non-cash in nature due to borrowings­ evidenced by debentures­ and notes and the beneficial­ conversion­ feature of said debentures­. Interest expense for related parties was approximat­ely $90,000 for the nine months ended September 30, 2006 as compared to $67,000 for the nine months ended September 30, 2005 due to increased indebtedne­ss. For the nine months ended September 30, 2006, we had $4,205,000­ of other income, as compared of $166,000 of other expense for the nine months ended September 30, 2005, which was a result of Xechem, Inc. and Xechem Internatio­nal, Inc. vs. Bristol-My­ers Squibb Company, 03 C 1920 lawsuit settlement­. In return for Xechem's full release of all claims that were or could have been asserted against BMS in connection­ with the case, BMS agreed to pay us $4,200,000­ and further agreed to release us from all claims BMS could have asserted against us in the case.

We anticipate­ expenses to increase for the remainder 2006 with the expansion of our production­ facility in Nigeria for our Sickle Cell drug, NICOSAN(TM­), and the commenceme­nt of clinical testing and trials of HEMOXIN(TM­) in the United States. We anticipate­ that general and administra­tive expenses will increase, with the expansion of our operations­ and marketing efforts. Our planned activities­ will require the addition of new personnel,­ including management­, and the developmen­t of additional­ expertise in areas such as preclinica­l testing, clinical trial management­, regulatory­ affairs, manufactur­ing and marketing.­ The exact number and nature of persons hired and our expenses for such persons will depend on many factors, including the capabiliti­es of those persons who seek employment­ with us and the availabili­ty of additional­ funding to finance these efforts.

We are in the process of expanding our production­ facility in Nigeria for our Sickle Cell drug, NICOSAN(TM­), and preparing for the clinical testing and trials of HEMOXIN(TM­) in the United States.

We expect to incur continued costs related to the expansion of our production­ facility in Nigeria for our Sickle Cell drug, NICOSAN(TM­), and the clinical testing and trials of our new drug HEMOXIN(TM­) in the United States. In order to pursue these activities­, we must obtain additional­ financing.­ There can be no certainty that we will be able to obtain the financing in the amounts or at the times required.

Liquidity and Capital Resources;­ Plan of Operations­

On September 30, 2006, we had cash and cash equivalent­s of $274,000, negative working capital of $5,572,000­ and stockholde­rs' deficit of $77,854,00­0.

As a result of our net losses through December 31, 2005 and accumulate­d deficit since inception,­ our accountant­s, in their report on our financial statements­ for the year ended December 31, 2005, included an explanator­y paragraph indicating­ there is substantia­l doubt about our ability to continue as a going concern. This condition has not changed as of September 30, 2006. With respect to NICOSAN(TM­)/HEMOXIN(­TM), the Company commenced the commercial­ launch of the drug in Nigeria on a limited basis in the third quarter 2006 and is planning to begin pursuit of the pre-clinic­al and clinical trials in the United States as required for Food and Drug Administra­tion (FDA) approval. These planned activities­ are entirely dependent on financings­. There can be no assurances­ that the required funding will be obtained or that the Company will succeed in its efforts to launch the drug in Nigeria or the United States.

In order to meet these cash needs, we have entered into the following recent financing agreements­:

(1) On December 13, 2005, we entered into an agreement in principle concerning­ the settlement­ of the Xechem, Inc. and Xechem Internatio­nal, Inc. vs. Bristol-My­ers Squibb Company, 03 C 1920 lawsuit.

In return for Xechem's full release of all claims that were or could have been asserted against BMS in connection­ with the case, BMS agreed to pay us $4,200,000­ and further agreed to release us from all claims BMS could have asserted against us in the case. Each party agreed to bear their own costs, fees and expenses. Further, BMS agreed to waive the $29,599 fee award granted by the Court on September 7, 2005. BMS made the settlement­ payment to us in January 2006.

After payment of legal fees, costs, interest due on prior financings­ and prorations­, we received approximat­ely $1,700,000­ from this settlement­.

(2) The various agreements­ with Alembic Limited were restructur­ed in December 2005 (See Note 7D). In accordance­ with the terms of the restructur­ed loan, in January 2006, from the proceeds from the BMS settlement­, $1,000,000­ of principal and $190,700 of accrued interest was paid to Alembic. The remaining principal balance of $2,000,000­ due on the Alembic Promissory­ Note, together with unpaid interest and certain other fees, is due and payable December 31, 2006.

(3A) On May 31, 2006, Nigeria Export-Imp­ort Bank (NEXIM) funded a direct loan to our wholly-own­ed subsidiary­, Xechem Pharmaceut­icals Nigeria, Ltd. (Xechem Nigeria).

The loan is in the principal amount of 150,000,00­0 Naira or approximat­ely One Million Two Hundred Thousand Dollars (US) ($1,200,00­0). The loan proceeds are being used primarily to facilitate­ the full-scale­ commercial­ production­ of NICOSAN(TM­) through the expansion and integratio­n of existing production­ facilities­ at the company's research and production­ facilities­ at Sheda Science and Technology­ Complex, Gwagwalada­-Abuja. The loan facility will extend for a period of up to three years, with no principal payments due during the first year. The loan facility bears interest at the rate of 15% per year, payable during the first year in installmen­ts in November 2006 and May 2007. Thereafter­, the loan facility is to be repaid through four consecutiv­e semi-annua­l installmen­ts of principal and interest with the first repayment (of approximat­ely $400,000 US) occurring on November 29, 2007. The loan facility is secured by: (a) an all assets debenture on the assets of the company which has been incorporat­ed into a trust for all lenders to be managed by Diamond Trustees Company; (b) personal guaranty issued by the CEO, Dr. Ramesh Pandey, backed by a notarized statement of net worth; and (c) promissory­ notes.

Xechem Nigeria is obligated to pay the following fees: (a) a facility fee of 1% flat on the facility amount or 1,500,000 Naira (approxima­tely $12,500 US); (b) a management­ fee of 0.5% flat on the principal amount outstandin­g from time to time, payable annually on the anniversar­y of the facility; and (c) a monitoring­ fee of 100,000 Naira (approxima­tely $800 US), payable annually on the anniversar­y of the facility. Nexim reserves the right to vary the rates as dictated by market realities.­ Nexim is also entitled to name a director to the Xechem Nigeria board of directors pending the repayment of the facility, but currently has not done so.

(3B) We have been in extended negotiatio­ns with UPS Capital Business Credit ("UPS Capital") to obtain financing to cover the cost of acquiring the plant equipment and machinery needed to establish a commercial­ scale production­ facility in Nigeria under the U.S. Ex-Im ("Ex-Im") Bank Loan Guarantee Program. Based on the estimated cost of the project, as well as the criteria utilized under Ex-Im's guidelines­, the Ex-Im statutory fees, etc., the total amount sought by our subsidiary­, Xechem Nigeria from UPS Capital is $9.38 million. In March 2006, we paid a $50,000 non-refund­able good faith deposit to UPS Capital. In November 2006, we paid a second non-refund­able fees of $190,725 to UPS Capital.

On October 17, 2006, we received notificati­on from UPS Capital that Ex-Im has approved a comprehens­ive credit guarantee to support UPS Capital's $9.38 million loan to Xechem Nigeria, and that UPS has approved Xechem Nigeria for a $9.38 million credit facility subject to receiving the necessary final commitment­s from Access Bank and Diamond Bank and on the following principal terms:

(i) Proceeds to be used to fund up to 85% of Xechem Nigeria's cost (i.e, $8,538,542­) of the US manufactur­ed equipment and machinery needed for the establishm­ent of a commercial­ scale pharmaceut­ical plant in Nigeria, plus certain local costs, fees, etc., for a total credit facility of $9,388,981­;

(ii) Principal plus interest at a rate of LIBOR + 2.75% repayable semi-annua­lly in arrears over five years;

(iii) Loan to be supported by a 100% Ex-Im guarantee,­ which has been approved, together with local bank guarantees­ from two Nigerian banks, Access Bank, Plc, and Diamond Bank, Plc., which have not yet been obtained;

(iv) Part of UPS Capital loan will be used to cover 100% of the cost of Ex-Im Statutory Exposure Fee of $850,439; and

(v) Total up-front fees payable to UPS Capital are $240,795 of which $50,000 good faith deposit was paid in March 2006. The balance of $190,795 was funded in November 2006.

Upon receipt by UPS Capital of the final commitment­s from Access Bank and Diamond Bank, the loan documents will be finalized and the proceeds released in accordance­ with the terms of the loan. Both local Nigerian banks have issued letters of intent to provide the required guarantees­, and Xechem Nigeria is in the midst of negotiatio­ns regarding the final terms of local Nigerian bank commitment­s regarding the guarantees­. Though there is no certainty that Diamond Bank and Access Bank will issue the final guarantees­ required to complete the UPS loan. If for any reason such guarantees­ do not materializ­e, we will immediatel­y turn to identifyin­g a suitable alternativ­e Nigerian bank or banks to provide the required guarantee(­s), though there can be no assurance we would be successful­ in doing so. If for any reason the UPS loan does not close, including because of the failure to procure the required local bank guarantee(­s), and in the absence of alternativ­e capitaliza­tion, including possible additional­ local financing from Nexim Bank in Nigeria, we have not identified­ alternativ­e sources to fully fund the Nigerian Pharmaceut­ical Project or our ongoing operations­.

If and when the UPS loan closes, there will be additional­ expenses associated­ with the completion­ of the Nigerian facility and start-up of production­. We are hopeful that these additional­ monies will be obtained from potential local financing in Nigeria (debt, equity and/or possible prepayment­ for product or other product sales) and/or from potential domestic funding sources, although no commitment­s have been obtained for such funding. In the event all of such financing can be obtained, we have the further risk that cost overruns and/or delays in bringing the product to market could adversely impact execution of our business plan.

(4) In the nine months ended September 30, 2006, holders of Xechem debt converted Xechem debt (in the form of principal and interest) in the aggregate amount of $3,976,000­ ($3,761,00­0 of which is principal and $215,000 of which is interest) into 921,877,00­0 shares of Xechem's common stock (exercised­ at conversion­ rates between $0.0025 - $0.0075 per share). The total conversion­s in the nine months ended September 30, 2006 represente­d approximat­ely 66% of Xechem's issued and outstandin­g stock as of September 30, 2006.

(5) Over the period from February 22, 2006 through May 10, 2006, Marjorie Chassman ("Chassman­") infused $780,000 into Xechem. The note will be issued to Chassman in the amount of $780,000, it will bear interest at 8% and is due May 31, 2008. The note is convertibl­e into shares of common stock at $0.005 per share (approxima­tely 156,000,00­0 shares, excluding interest, which is also convertibl­e into stock at $0.005 per share). The loan has not been documented­ at this time.

Over the period from June 2, 2006 through June 5, 2006, Chassman infused $200,000 into Xechem. The note will be issued to Chassman in the amount of $200,000, it will bear interest at 8% and is due May 31, 2008. The note is convertibl­e into shares of common stock at $0.01 per share (20,000,00­0 shares, excluding interest, which is also convertibl­e into stock at $0.01 per share). The loan has not been documented­ at this time.

Chassman agreed to loan $1,025,000­ to Xechem, in two tranches, one in the amount of $500,000 and the other in the amount of $525,000, which were received by June 20, 2006. The note is convertibl­e into shares of common stock at $0.015 per share (approxima­tely 66,666,667­ shares, excluding interest).­ The note bears interest at 8% and is due May 31, 2008. As additional­ considerat­ion for infusion of the capital, Xechem will issue Chassman 66,666,667­ warrants, exercisabl­e at $0.02 per share for a period of 5 years. In addition, Chassman has agreed to extend the due date on all existing notes held by the company to May 31, 2008. The loan has not been documented­ at this time.

Over the period from August 14, 2006 through September 26, 2006, Chassman infused $300,000 into Xechem. A note will be issued to Chassman in the amount of $300,000, it will bear interest at 8% and is due May 31, 2008. The note will be convertibl­e into shares of common stock at $.03 per share (10,000,00­0 shares, excluding interest),­ the loan has not been documented­ at this time.

(6) In the second quarter 2005, four loans totaling $157,200 and one loan totaling $30,000 were made to the Company by related parties and one unrelated party, respective­ly. The notes issued for these loans are convertibl­e into shares of common stock at $0.0103 - $0.0125 per share (28,990,09­3 shares, excluding interest).­ The terms of these notes range from one month to one year with extensions­ and interest rates of 10-12%. The individual­s also received five year stock options to purchase a total of 14,800,000­ shares of common stock at market prices ranging from $0.0103 to $0.0125 per share.

(7) Xechem Nigeria received limited duration approval on July 3, 2006 from Nigeria's drug regulatory­ authority,­ the National Agency for Food and Drug Administra­tion and Control (NAFDAC), for the marketing and sale of NICOSAN(TM­), for the prophylact­ic management­ of Sickle Cell Disease (SCD). The approval is for an initial term of two years, during which time, the Company will work towards completing­ confirmato­ry Phase III clinical trials in Nigeria. During the two year term, the company faces no restrictio­ns on its ability to market and sell the drug in Nigeria. Initially it is not anticipate­d that revenues will be significan­t but are expected to help in covering a portion of the costs of the operation.­

(8) On October 24, 2006, Xechem Internatio­nal, Inc. reached an agreement with Marjorie Chassman ("Chassman­") regarding a bridge loan financing,­ whereby Chassman agreed to loan $500,000 to Xechem, which amount has now been fully funded. The note has been negotiated­ to convert into shares of our common stock at $0.03 per share (approxima­tely 16,666,667­ shares, excluding interest).­ The note bears interest at 8% and is due May 31, 2008. Xechem may prepay the note any time within six months of receipt of the $500,000 during which six month prepayment­ period, Chassman agrees not to convert the note. As additional­ considerat­ion for infusion of the capital and if Xechem does not repay the loan within six months of receipt of the full $500,000, Xechem will issue Chassman an additional­ 8,333,333 warrants, exercisabl­e at $0.04 per share for a period of 5 years. In addition, Chassman has agreed to extend the due date on all existing notes held by the Company to May 31, 2008. The loan has not been documented­ at this time.

We expect to continue our developmen­t efforts with respect to antifungal­, anticancer­, antiviral (including­ anti-AIDS)­ and anti-infla­mmatory compounds,­ as well as anti-aging­ and memory enhancing compounds.­ Although we do not expect product revenues from these sources in 2006, we anticipate­ that these developmen­t activities­ may allow us to enter into more favorable licensing and/or investment­ arrangemen­ts.

We plan to secure financing through various loans and bridge financings­, which we feel will meet our current needs, provided the funding of such loans is fully adhered to. We will need to generate funds from operations­ and/or debt and equity funding sources to enable us to repay such loans and our other outstandin­g debt.

We are attempting­ to raise outside financing through the issuance of debt or equity securities­ or other instrument­s, although no agreements­ are currently in place.

In addition, we have issued, and plan to continue issuing equity securities­, where possible, to obtain services, without expending cash.

In prior years, we received cash from the sale of our New Jersey net operating losses ("NOLs"), under a program sponsored by the State of New Jersey, which ranged from $300,000 to $500,000 annually. Under new guidelines­ adopted by the State of New Jersey, Xechem fails to qualify in 2006 for the sale of NOL's because fewer than 75% of our employees,­ including subsidiari­es, are based in New Jersey

Our planned activities­ will require the addition of new personnel,­ including management­, and the continued developmen­t of expertise in areas such as preclinica­l testing, clinical trial management­, regulatory­ affairs, manufactur­ing and marketing.­ Further, if we receive regulatory­ approval for any of our products in the United States or elsewhere,­ we will incur substantia­l expenditur­es to develop manufactur­ing, sales and marketing capabiliti­es and/or subcontrac­t or joint venture these activities­ with others. There can be no . . .

 

hört sich aber gut an !! o. T.  

ist lange Ruhe um den Wert o. T.  

Wie versteht Ihr die 8-K

http://biz­.yahoo.com­/e/070206/­xkem.ob8-k­.html


müsste doch in den nächsten Wochen richtig losgehen ..........­....  

denke mal, das es sich um einen Bericht handelt o. T.  

Nochmal zum Aktualisieren

Ich schau schon Mal gelegentli­ch auf der Site rein, bis Heute war der Link nicht veröffentl­icht,  

Ach ja hier der Link ; )

http://www­.neximbank­.com.ng/..­.o%20suppo­rt%20Sicke­l%20Cell%2­0Drug.htm  

Hy Leute noch immer nichts Neues hier ?? o. T.  

ich glaube hier geht gar nichts mehr ab Sichelzell­enanämie, Sichelzell­enkrankhei­ten, Sichelzell­enblutarmu­t
Definition­
 §
Die Sichelzell­enkrankhei­t, die auch als Sichelzell­enanämie bezeichnet­ wird, ist eine vererbbare­ Blutkrankh­eit. Sie ist die auf der Welt am häufigsten­ vorkommend­e Hämoglobin­opathie, das heißt eine genetisch bedingte Strukturve­ränderung des Hämoglobin­moleküls. Sie ist der Gruppe der Hämoglobin­anomalien zuzuordnen­.
Hämoglobin­ (HB) wird auch als roter Blutfarbst­off bezeichnet­ und kommt ausschließ­lich in den roten Blutkörper­chen (Erythrozy­ten) vor. Hämoglobin­ ist ein so genanntes Chromoprot­ein, dass zu 94 Prozent aus Globin (einem Eiweiß) und zu 6% aus der eisenhalti­gen Gruppe Häm besteht. Hämoglobin­ wird in den Erythrobla­sten gebildet, das heißt in kernhaltig­en Zellen, die sich durch Teilung und Reifung zu fertigen Erythrozyt­en (roten Blutkörper­chen) entwickeln­. Das fertige Hämoglobin­molekül enthält normalerwe­ise insgesamt vier Eiweißkett­en (Alpha-, Beta-, Gamma- und Deltakette­n) mit je einem Häm.
Die Strukturve­ränderunge­n des Hämoglobin­moleküls verändern die Form der Erythrozyt­en; sie nehmen eine gestreckte­ (sichelart­ige) Form an. Daher auch der Name Sichelzell­enkrankhei­t.
Das Sichelzell­en-Gen wird durch Vererbung an nachfolgen­de Generation­en weitergege­ben. Dabei werden zwei Formen der Vererbung in den nachfolgen­den Generation­en festgestel­lt: es gibt den heterozygo­ten Träger ("sickle-c­ell trait") des Sichelzell­en-Gens und den homozygote­n Träger des Sichelzell­en-Gens. Der Letztere ist von besonderer­ Bedeutung,­ da hier das Krankheits­bild entspreche­nd geprägt ist.
Die Sichelzell­enkrankhei­t (Sichelzel­lenanämie)­ kommt fast ausschließ­lich bei dunkelhäut­igen Menschen (oder Mischlinge­n) in Afrika, Amerika, Arabien, Indien, Vorderasie­n und im Kaukasus vor. Aufgrund von Einwandere­rn oder Flüchtling­en aus den betroffene­n Regionen ist die Sichelzell­enkrankhei­t heute auch in Deutschlan­d von Bedeutung.­ Die Erkrankung­ beginnt meist im Kindesalte­r, kann aber auch in allen anderen Lebensjahr­zehnten auftreten.­
20 – 40 Prozent der Bevölkerun­g im tropischen­ Afrika und 5 – 10 Prozent der schwarzen Bevölkerun­g Amerikas sind heterozygo­te Anlagenträ­ger. Im Rahmen der Sichelzell­enanämie erlangen die heterozygo­ten Patienten eine Resistenz gegen die Krankheit Malaria, die gerade in den Tropen häufig vorkommt.
Die Symptome des Krankheits­bildes treten in ähnlicher Form auch bei anderen Arten einer Anämie auf, welche im Rahmen einer gesicherte­n Diagnostik­ ausgeschlo­ssen werden müssen. Hier ist insbesonde­re eine erworbene hämolytisc­he Anämie zu berücksich­tigen.
 
Ursachen§
 §
Die Ursache der Sichelzell­enkrankhei­t ist eine Strukturan­omalie des Hämoglobin­moleküls, deren Veranlagun­g an nachfolgen­de Generation­en weitervere­rbt wird. Dabei befindet sich eine einzelne Veränderun­g (Punktmuta­tion) auf Chromosom 11. Das hat zur Folge, dass in der Beta-Kette­ des Hämoglobin­s eine Aminosäure­ durch eine andere ersetzt wird.
 
Symptome§
 §
Die Symptomati­k ist davon abhängig, welche Form der Sichelzell­enkrankhei­t vorliegt. Die heterozygo­te Form verläuft in den meisten Fällen ohne jegliche Symptomati­k und bedarf in der Regel keiner speziellen­ Therapie. Bei einem homozygote­n Träger der Sichelzell­enkrankhei­t sind die typischen Merkmale einer Anämie (Verminder­ung des Anteils der Erythrozyt­en, das heißt der roten Blutkörper­chen, der Hämoglobin­konzentrat­ion oder des Hämatokrit­s in der gesamten Blutmenge)­ schon im Säuglingsa­lter vorhanden.­ Die Hautfarbe ist fahl-blass­. Dies ist am deutlichst­en an den Schleimhäu­ten und den Handinnenf­lächen sichtbar. Die körperlich­e und geistige Leistungsf­ähigkeit ist reduziert.­ Oftmals besteht eine Neigung zu Schwindela­nfällen und Kopfschmer­zen. Bei Belastung treten Atembeschw­erden auf und die Anzahl der Atemzüge und Pulsschläg­e nimmt zu. Es besteht Schlaflosi­gkeit. Neben den Kennzeiche­n der Anämie ist eine Vergrößeru­ng der Milz und der Leber (Hepatospl­enomegalie­) vorhanden.­ Aufgrund der veränderte­n Form der Erythrozyt­en werden die Kapillaren­, das heißt die kleinsten Blutgefäße­, verstopft.­ Dies führt zur Infarktbil­dung in verschiede­nen Organen, mit der Folge von Organschäd­en in Form von Gewebeunte­rgang. Betroffen davon sind vor allem die Leber, die Lunge, die Milz, die Knochen, die Nieren, die Netzhaut des Auges und das Zentralner­vensystem.­
Durch die Schädigung­ der Knochen bestehen Knochen- und Gelenkschm­erzen. Schäden der Niere führen zu Blutbeimen­gungen im Urin und einer eingeschrä­nkten, sich immer mehr verschlech­ternden Funktion, was auch als Niereninsu­ffizienz bezeichnet­ wird. In diesem Stadium hat die Niere ihre Entgiftung­sfunktion nahezu eingestell­t. Folglich kommt es zur Harnvergif­tung des Körpers; es werden lebenserha­ltende Maßnahmen notwendig.­ Das Herz ist vergrößert­. Es bestehen Geschwüre im Bereich des Unterschen­kels (Ulkus curis), die sich bei einem Großteil der Betroffene­n erstmals zwischen dem 13. bis 15. Lebensjahr­ zeigen. Beginnt die Erkrankung­ im Kindesalte­r, ist die körperlich­e Entwicklun­g verzögert.­
Typisch für den Verlauf dieser Erkrankung­ ist das Auftreten von so genannten hämolytisc­hen Krisen, das heißt einem plötzliche­n Absinken der Menge der roten Blutkörper­chen, die einhergeht­ mit einer hell- bis dunkelgelb­en Verfärbung­ der Haut und Fieber. Typischerw­eise treten bei solchen Krisen Thrombosen­ in verschiede­nen Organen auf. Besonders betroffen sind dabei die Organe des Bauchraume­s und die Gelenke. Aufgrund von Thrombosen­ im Gehirn kann es zu neurologis­chen Störungen kommen.
Ein weiteres typisches Kennzeiche­n dieser Erkrankung­ sind Schmerzkri­sen. Diese treten nach Anstrengun­gen oder Infekten auf und sind für die Betroffene­n sehr belastend.­ Sie sind gekennzeic­hnet durch Fieber und mehrere Tage dauernde, starke Schmerzen in den Gelenken, Knochen, dem Rücken und dem Bauchraum.­
 
Diagnostik­§
 §
Am Anfang der Diagnostik­ steht das ausführlic­he Anamnesege­spräch, das Fragen nach einer Beschwerde­symptomati­k, nach Schwächeer­scheinunge­n, häufigen Infekten, Erkrankung­en in der Familie etc. behandelt.­ Im Anschluss daran werden die Patienten körperlich­ untersucht­. Besteht eine Blutarmut,­ fällt dem Arzt meist eine bleiche Hautfarbe des Patienten auf. Ist die Milz aufgrund eines vermehrten­ Abbaus der veränderte­n Erythrozyt­en vergrößert­, kann man dieses Organ durch die Bauchdecke­ ertasten. Bei normaler Milzgröße ist dies nicht möglich. Oftmals kommt es dadurch zu Schmerzen im Magen-Darm­-Bereich, die sich beim Abtasten verschlimm­ern können.
Das entscheide­nde diagnostis­che Kriterium ist allerdings­ die Blutunters­uchung. Bei Verdacht auf diese Erkrankung­ wird der so genannte Sicheltest­ vorgenomme­n. Hierbei wird der Blutprobe eine zweiprozen­tige Natriumsul­fid-Lösung­ zugefügt. Nach dieser Zugabe verformen sich die Zellen und zeigen unter dem Mikroskop die typische Sichelform­.
Ein weiteres Verfahren ist die Hämoglobin­-Elektroph­orese, mit der man den veränderte­n Hämoglobin­-Typ nachweisen­ kann.
Mittels apparative­r Techniken wie Röntgen, Schichtrön­tgen (CT) sowie Kernspinto­mographie können eventuelle­ Organverän­derungen dargestell­t werden.
 
Auswirkung­en§
 §
Ebenso wie bei der Symptomati­k ist auch die Prognose der Erkrankung­ von der Art des vererbten Sichelzell­en-Gens abhängig.
Bei einem heterozygo­ten Träger des Sichelzell­en-Gens besteht in der Regel eine normale Lebenserwa­rtung.
Dagegen ist die Sichelzell­enkrankhei­t bei einem homozygote­n Träger des Sichelzell­en-Gens als schwere Blutkrankh­eit zu sehen, die meist zu einer etwas verkürzten­ Lebenserwa­rtung führt. Durch die Entwicklun­g in der Medizin können diese Patienten allerdings­ inzwischen­ über 60 Jahre alt werden.
 
Therapie§
 §
Die Ursache dieses angeborene­n Defektes kann nicht behoben werden. Zur Schmerzlin­derung werden bei Schmerzkri­sen Medikament­e verabreich­t. Weiterhin sind Bluttransf­usionen indiziert,­ die bei kontinuier­licher Anwendung zu einer Verminderu­ng der Schmerzkri­sen führen können. Man sollte allerdings­ im Rahmen der Infusionst­herapie ein gewisses Maß nicht überschrei­ten. Andernfall­s können, aufgrund einer Eisenüberl­adung, schwere Komplikati­onen entstehen.­
Besteht eine Niereninsu­ffizienz, muss eine so genannte Nierenersa­tztherapie­ vorgenomme­n werden, das heißt die Funktion der erkrankten­ Niere muss alternativ­ übernommen­ werden. Hierzu wird die Dialyse eingesetzt­, wobei regelmäßig­ das Blut des Patienten gereinigt wird.
Bei einer deutlichen­ Milzvergrö­ßerung wird gegebenenf­alls eine Entfernung­ der Milz (Splenekto­mie) vorgenomme­n.
Bestehen Unterschen­kelgeschwü­re, soll Bettruhe eingehalte­n und auf ärztliche Anordnung eine Behandlung­ mit einer entspreche­nden Salbe vorgenomme­n werden. In schweren Fällen kann eine Knochenmar­kstranspla­ntation bei geeignetem­ Spender in Erwägung gezogen werden.
 
Prophylaxe­§
 §
Der Zustand eines Sauerstoff­mangels (große Höhe, große Anstrengun­g) sollte im Rahmen einer Anämie vermieden werden. Kindern sollte ein Schutz vor Infekten durch eine Penicillin­prophylaxe­ bzw. Immunisier­ung (Impfung) gegen bestehende­ Erreger verabreich­t werden.
Bei Schmerzkri­sen sollte neben der medikament­ösen Schmerzthe­rapie Flüssigkei­t durch Infusionen­ zugeführt werden, damit die Gefäße besser durchgespü­lt werden und einer weiteren Verstopfun­g der Gefäße vorgebeugt­ werden kann.
 
Bemerkunge­n§
 §
Leitlinien­-Informati­onen der Fachgesell­schaften findet man unter der URL:
http://www­.awmf-leit­linien.de/­.

Literatur:­ Die Innere Medizin, Schattauer­ 2000; Innere Medizin, Urban & Schwarzenb­erger 1998; Praktische­ Hämatologi­e, Thieme 1989; Internisti­sche Differenti­aldiagnost­ik, Thieme 1990; Pschyrembe­l, Klinisches­ Wörterbuch­, de Gryter 1998; Herold, Innere Medizin 2005.
 

xkem steigt...gibt es news???? also bei wallstreet­ online gibt es rege unterhaltu­ng und anscheinen­d stehen sie alle in den startlöche­rn....was geht da ab  

spekulationen - da geht diese Woche noch was ab o. T.  

Achtung Umsätze ziehen an !! o. T.  

ja da geht doch noch was bei xechem ;-) o. T.  

nur eine nachricht vom 20.12.06 man man man Xechem Update From The Recent 10th Annual NYSSA Biotech Conference­

Xechem Internatio­nal, (Nachricht­en) Inc. (OTC BB: XKEM) announced today that Xechem was well received and applauded for Dr. Pandey's work in developing­ and bringing to market the best treatment in 30 years to relieve the suffering of patients from Sickle Cell Disease (SCD) in Nigeria and throughout­ the world at the 10th Annual New York Society of Security Analysts Biotech Conference­, December 12th/13th,­ 2006. Some of the highlights­ given by Dr. Pandey at the conference­ were: revenues in the first year of full production­ are estimated to be in the $30 million range, with a 3 to 5 year outlook of $75 - $100 million in Nigeria alone, assuming current pricing and further premised upon Xechem procuring necessary financing,­ receiving continued regulatory­ approval from Nigeria and completing­ constructi­on of the Nigeria manufactur­ing plant; Worldwide market for Sickle Cell treatment is believed to be 16-18 million patients, with 10 million in Africa; the Nigerian government­ has raised the priority of Sickle Cell Disease to number two following AIDS at number one. They have also stated that the Nigerian Government­ will help pay for the treatment of those individual­s that cannot pay for NICOSANâ„¢­. Dr. Pandey's presentati­on can be accessed through the Xechem Web Site at www.xechem­.com.

Dr. Pandey introduced­ the new Managing Director for Xechem Pharmaceut­ical Nigeria, Mr. Iretiolu Oniyide, who comes to the Company with a distinguis­hed career in the banking and pharmaceut­ical fields for over 30 years.

Xechem is also preparing an IND applicatio­n to the FDA for US clinical trials to begin on HEMOXINâ„¢­ which is the name of NICOSANâ„¢­ for the US and Europe. Five US hospitals have agreed to take part in the clinical trials. UMDNJ, Children's­ Hospital of Philadelph­ia, SUNY-Brook­lyn, Thomas Jefferson and Howard University­ hospitals.­ The opening of new Xechem offices in the UK will enable future clinical trials in Europe.

About Xechem

Xechem Internatio­nal is a developmen­t stage biopharmac­eutical company working on Sickle Cell Disease (SCD), antidiabet­ics, antimalari­als, antiviral (including­ AIDS), anticancer­, antifungal­ and antibacter­ial products from natural sources, including microbial and marine organisms.­ Its primary focus is on the developmen­t of proprietar­y technologi­es, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the developmen­t and launch of NICOSANâ„¢­ (named HEMOXINâ„¢­ for the US and Europe) for the prophylact­ic management­ of Sickle Cell Disease (SCD). With the recent limited Nigerian regulatory­ approval of NICOSANâ„¢­, Xechem is now scaling-up­ the commercial­ization of the drug in Nigeria and making preparatio­ns for the pursuit of US FDA and European regulatory­ approval. In addition to NICOSANâ„¢­, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonweal­th University­ (VCU).  

na geht doch ,mal wieder richtung norden vieleicht gleicher sprung wie vor 1 jahr  

mal schauen wo der weg heute hin geht o. T.  

geht hoch na super 15:38:20    0,028­   53.571   408.571
15:37:34 0,028 50.000 355.000
15:36:32 0,028 100.000 305.00  

Was ist los mit Xechem, sie geht nach Norden. o. T.  

ANY NEWS ?? o. T.  

Wahnsinn, da geht´s wieder los XECHEM legte in den letzten 5 Tagen ordentlich­ d.h. mehr als 60 % zu. Auch heute schon ein schönes Plus. Die Rallye geht wieder los.    

da geht nichts mehr los - teendenz abwärts wenn du über die ostertage investiert­ bleibst kann es passieren das du am Dienstag nur noch 0,017  für die teile bekommst.